[{"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123-001", "question": "A 58-year-old woman with hypertrophic cardiomyopathy presents with recurrent syncope despite maximum-dose beta-blocker therapy. Echocardiography reveals a resting left ventricular outflow tract (LVOT) gradient of 85 mmHg, systolic anterior motion of the mitral valve, and septal thickness of 22 mm. Coronary angiography shows a large first septal perforator arising from the left anterior descending artery supplying the basal septum. She is referred for alcohol septal ablation. During the procedure, after balloon occlusion of the septal perforator and injection of echocardiographic contrast, opacification is noted in the papillary muscle region in addition to the target septal area. What is the most appropriate next step?", "options": ["Proceed with alcohol injection as planned given adequate septal opacification", "Abort the procedure and refer for surgical myectomy", "Advance the balloon more distally and reassess contrast distribution", "Reduce the planned alcohol volume by 50% and proceed", "Switch to a different septal perforator branch if available"], "answer": "C", "answer_index": 2, "explanation": "Papillary muscle opacification during alcohol septal ablation indicates that alcohol injection would cause papillary muscle necrosis, potentially resulting in severe mitral regurgitation. The appropriate step is to reposition the balloon more distally to exclude the branch supplying the papillary muscle. Proceeding with injection (A) or reducing volume (D) risks catastrophic mitral regurgitation. Aborting immediately (B) is premature before attempting repositioning. Switching perforators (E) may be considered only if repositioning fails and another suitable branch exists.", "generator_model": "claude-opus-4-5-20251101", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The patient is undergoing alcohol septal ablation for obstructive hypertrophic cardiomyopathy. Myocardial contrast echocardiography (MCE) is a critical step performed before the injection of alcohol to delineate the vascular territory of the septal perforator branch.\n\nThe key finding is that the contrast agent opacifies the target basal septum as well as the papillary muscle region.\nInjection of alcohol into a vessel supplying the papillary muscles is an absolute contraindication at that specific site because it can lead to papillary muscle necrosis, rupture, and severe acute mitral regurgitation, which is life-threatening.\n\nTherefore:\nA. Proceeding with alcohol injection is incorrect and dangerous.\nD. Reducing the alcohol volume does not eliminate the risk of necrosis in the non-target tissue; it is incorrect.\n\nThe operator must ensure that the alcohol is delivered *only* to the target septal myocardium. When a septal perforator supplies non-target structures (like the papillary muscle or LV free wall), the anatomy at that specific occlusion site is unsuitable. However, this does not immediately rule out the entire vessel or procedure. The branch supplying the papillary muscle often arises proximally from the septal perforator.\n\nThe most appropriate next step is to attempt to exclude the non-target branch while maintaining access to the target myocardium. This is commonly done by advancing the balloon catheter more distally within the septal perforator and repeating the contrast injection (MCE). If the branch to the papillary muscle takes off proximally to the new balloon position, the distal injection will safely opacify only the septum.\n\nE. Switching to a different septal perforator is a reasonable alternative if repositioning fails or if the vessel is unsuitable, but trying to optimize the position in the *primary* target vessel (the large first septal which supplies the basal blockade) is the first troubleshooting step.\nB. Aborting the procedure and referring for surgery is the final recourse if no safe septal perforator can be found or positioned. It is not the *immediate* next step before attempting to reposition the balloon.\n\nTherefore, one must try to reposition the balloon and reassess to see if the dangerous territory can be excluded.\n\nThe answer is (C)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123-002", "question": "A 34-year-old man presents with progressive gait instability and cognitive decline over 18 months. Examination reveals vertical supranuclear gaze palsy, axial rigidity greater than limb rigidity, early postural instability with falls, and frontal release signs. Brain MRI shows midbrain atrophy with the 'hummingbird sign.' Genetic testing reveals a heterozygous mutation in the MAPT gene. His father died at age 45 with a similar presentation. Which tau isoform predominates in the neuropathological inclusions of this patient's condition?", "options": ["3-repeat tau (3R) exclusively", "4-repeat tau (4R) exclusively", "Mixed 3R and 4R tau in equal proportions", "Hyperphosphorylated tau without repeat domain specificity", "Truncated tau lacking the microtubule-binding domain"], "answer": "B", "answer_index": 1, "explanation": "This presentation describes progressive supranuclear palsy (PSP) phenotype associated with MAPT mutation. PSP is a 4-repeat (4R) tauopathy, with tau inclusions composed predominantly of 4R tau isoforms. Pick disease is characterized by 3R tau (A), while Alzheimer disease shows mixed 3R/4R tau (C). The tau in PSP is hyperphosphorylated but specifically 4R predominant, making (D) incomplete. Truncated tau (E) is not characteristic of PSP pathology.", "generator_model": "claude-opus-4-5-20251101", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "This patient presents with a classic clinical phenotype of Progressive Supranuclear Palsy (PSP), evidenced by vertical supranuclear gaze palsy, early postural instability (falls), axial rigidity, and the characteristic \"hummingbird sign\" (midbrain atrophy) on MRI. Additionally, the young age of onset and family history point to a hereditary cause, confirmed by the *MAPT* mutation (Frontotemporal Dementia with Parkinsonism linked to chromosome 17, or FTDP-17).\n\nTauopathies are classified based on the predominant tau isoform found in the pathological inclusions. The tau gene (*MAPT*) undergoes alternative splicing, specifically involving exon 10. Inclusion of exon 10 results in 4-repeat (4R) tau, while exclusion results in 3-repeat (3R) tau.\n\n*   PSP and Corticobasal Degeneration (CBD) are classified as 4R tauopathies. In familial cases (FTDP-17) that present with a PSP-like phenotype, the underlying *MAPT* mutations typically affect the splicing of exon 10 to increase the ratio of 4R to 3R tau, leading to 4R-predominant inclusions.\n*   Pick's disease is a 3R tauopathy.\n*   Alzheimer's disease is characterized by mixed 3R and 4R tau (paired helical filaments).\n\nTherefore, the condition described (PSP phenotype caused by a *MAPT* mutation) is associated with inclusions in which 4-repeat tau predominates.\n\nThe answer is (B)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123-003", "question": "A 42-year-old woman with type 1 diabetes mellitus on insulin pump therapy presents with recurrent episodes of neuroglycopenia occurring 3-4 hours postprandially despite appropriate carbohydrate counting and bolus dosing. Continuous glucose monitoring shows rapid glucose drops from 180 mg/dL to 45 mg/dL within 90 minutes after meals. Gastric emptying study is normal. Anti-insulin antibodies are markedly elevated at 85% binding (normal <5%). Which mechanism best explains her hypoglycemic episodes?", "options": ["Antibody-mediated accelerated insulin clearance causing initial hyperglycemia followed by rebound hypoglycemia", "Antibody buffering of exogenous insulin with delayed release causing prolonged insulin action", "Cross-reactivity of anti-insulin antibodies with insulin receptors causing receptor activation", "Antibody-induced insulin resistance requiring higher doses with subsequent overdosing", "Complement-mediated destruction of pancreatic alpha cells reducing glucagon counterregulation"], "answer": "B", "answer_index": 1, "explanation": "Insulin autoimmune syndrome (IAS) or exogenous insulin antibody syndrome involves high-affinity anti-insulin antibodies that bind circulating insulin, creating a 'buffer' reservoir. This causes initial postprandial hyperglycemia (insulin bound and inactive), followed by delayed hypoglycemia when insulin dissociates from antibodies hours later. This explains the pattern of post-meal hyperglycemia followed by delayed severe hypoglycemia. Accelerated clearance (A) would cause persistent hyperglycemia. Receptor cross-reactivity (C) and alpha cell destruction (E) are not mechanisms of anti-insulin antibodies.", "generator_model": "claude-opus-4-5-20251101", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "This patient presents with recurrent late postprandial hypoglycemia in the setting of Type 1 Diabetes and markedly elevated anti-insulin antibodies. This clinical picture is characteristic of the \"depot\" or \"reservoir\" effect caused by high titers of insulin-binding antibodies.\n\n1.  Mechanism: The anti-insulin antibodies bind a significant proportion of the administered bolus insulin immediately after injection. This \"buffering\" effect sequesters the insulin, preventing it from acting immediately and potentially causing early postprandial hyperglycemia.\n2.  Delayed Release: As time passes and the concentration of free insulin declines (or due to the dissociation kinetics of the antibody-insulin complex), the bound insulin dissociates from the antibodies.\n3.  Result: This release typically occurs 3-4 hours postprandially. At this time, the glucose load from the meal has already been cleared. The release of this \"stored\" insulin creates a state of relative hyperinsulinemia that does not match the blood glucose level, precipitating hypoglycemia.\n\nThis phenomenon explains the specific timing (late postprandial) and the association with high antibody binding capacity.\n\n*   Option A is incorrect because accelerated clearance would lead to reduced insulin effect (hyperglycemia) but not necessarily rebound hypoglycemia, and antibodies usually prolong half-life rather than shorten it.\n*   Option C describes Type B Insulin Resistance, which involves antibodies against the *insulin receptor*, not insulin itself.\n*   Option D describes a consequence (resistance) but lacks the specific kinetic explanation (delayed release) that accounts for the timing of the hypoglycemia relative to the meal and bolus.\n*   Option E is not a known mechanism for anti-insulin antibodies.\n\nThe answer is (B)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123-004", "question": "A 67-year-old man with ischemic cardiomyopathy (LVEF 25%) and cardiac resynchronization therapy-defibrillator (CRT-D) presents for device interrogation. He reports improved functional capacity since implantation 6 months ago. Interrogation reveals 94% biventricular pacing. However, the device electrograms show that during intrinsic AV conduction, the LV lead captures occurs 40 ms after RV lead capture, and during biventricular pacing, LV capture occurs 15 ms before RV capture. His current AV delay is programmed at 120 ms sensed/150 ms paced. What programming change would most likely optimize his cardiac resynchronization?", "options": ["Shorten the AV delay to 80 ms sensed/110 ms paced", "Lengthen the AV delay to 180 ms sensed/210 ms paced", "Program VV delay with RV preceding LV by 40 ms", "Program VV delay with LV preceding RV by 30 ms", "Enable automatic AV and VV optimization algorithm"], "answer": "A", "answer_index": 0, "explanation": "The electrogram findings indicate that intrinsic conduction results in significant LV delay (LV activates 40 ms after RV), consistent with left bundle branch block pattern. During BiV pacing, LV leads RV by only 15 ms, suggesting suboptimal resynchronization. The key issue is that with a 120 ms AV delay, there may be fusion with intrinsic conduction compromising true biventricular capture. Shortening the AV delay ensures complete ventricular capture by the device before intrinsic conduction, maximizing resynchronization benefit. Programming RV to precede LV (C) would worsen the native LBBB pattern. Lengthening AV delay (B) would increase fusion. While automatic algorithms (E) exist, the specific findings here indicate the need for shorter AV delay.", "generator_model": "claude-opus-4-5-20251101", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "This patient with appropriate CRT indications and improved functional capacity presents with 94% biventricular pacing. While 94% indicates significant delivery of therapy, maximal benefit in CRT is derived from achieving >98-99% bi-ventricular pacing. A pacing percentage of 94% suggests frequent loss of biventricular capture, most likely occurring during physical activity when the intrinsic heart rate increases and the intrinsic PR interval shortens, allowing intrinsic conduction to override the programmed AV delay.\n\nThe current programmed sensed AV delay is 120 ms. If the patient's intrinsic conduction shortens to <120 ms during exercise, the device will inhibit pacing, leading to loss of CRT (fusion or pure intrinsic beats) which is detrimental.\n\nAmong the options provided:\n*   A. Shorten the AV delay to 80 ms sensed/110 ms paced: This intervention will ensure that the device paces the ventricles before the intrinsic conduction can occur, even during exercise when the PR interval shortens. This will increase the biventricular pacing percentage toward 100%, which is the primary goal to optimize CRT response and reduce mortality.\n*   B. Lengthening the AV delay would increase intrinsic conduction and further reduce the pacing percentage.\n*   C & D. Changing the VV delay addresses the timing of the paced beats but does not solve the issue of the 6% of beats that are not being paced at all. With an intrinsic RV-LV delay of 40 ms (relatively short) and current programming of LV first by 15 ms, the current timing is likely acceptable. The most pressing issue is the quantity of pacing.\n*   E. Enabling an optimization algorithm is a reasonable step, but static optimization algorithms run at rest might not account for exercise-induced PR shortening significantly enough to cure the 94% issue unless specific rate-adaptive features are involved. Manually shortening the AV delay is the direct and definitive answer for \"fixing\" suboptimal pacing percentages in exam scenarios.\n\nTherefore, ensuring consistent capture by shortening the AV delay is the best optimization.\n\nThe answer is (A)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123-005", "question": "A 29-year-old woman presents with acute onset of right-sided weakness and aphasia. CT head is negative for hemorrhage. CT angiography reveals complete occlusion of the left middle cerebral artery M1 segment. CT perfusion shows a small core infarct (8 mL) with large penumbra (95 mL mismatch). Her NIHSS is 18. Time last known well is 2 hours ago. She has a history of antiphospholipid syndrome with prior deep vein thrombosis, currently on warfarin with INR of 3.2. What is the most appropriate acute intervention?", "options": ["Intravenous alteplase followed by mechanical thrombectomy", "Mechanical thrombectomy alone without intravenous thrombolysis", "Intravenous alteplase alone with close monitoring", "Administer 4-factor prothrombin complex concentrate then IV alteplase and thrombectomy", "Anticoagulation reversal with idarucizumab followed by mechanical thrombectomy"], "answer": "B", "answer_index": 1, "explanation": "This patient has a large vessel occlusion with favorable perfusion imaging (small core, large penumbra) within the thrombectomy window. However, her INR of 3.2 is a contraindication to IV alteplase (INR >1.7 is exclusion criterion). Mechanical thrombectomy is not contraindicated by anticoagulation status and should be performed emergently. IV alteplase (A, C) is contraindicated with therapeutic anticoagulation. PCC reversal followed by alteplase (D) delays definitive treatment and alteplase remains relatively contraindicated even after reversal. Idarucizumab (E) reverses dabigatran, not warfarin.", "generator_model": "claude-opus-4-5-20251101", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "This question addresses the acute management of ischemic stroke in a patient who is therapeutically being anticoagulated with warfarin.\n\n1.  Patient Status: The patient is presenting with a large vessel occlusion (LVO) of the left MCA M1 segment and a severe clinical deficit (NIHSS 18).\n2.  Imaging: CT perfusion shows a large mismatch (small core, large penumbra), indicating salvageable brain tissue.\n3.  Contraindication to Thrombolysis: The patient is currently taking warfarin and has an INR of 3.2. According to American Heart Association/American Stroke Association (AHA/ASA) guidelines, intravenous alteplase is contraindicated in patients taking warfarin if the INR is > 1.7. Therefore, she cannot safely receive IV thrombolysis (Options A and C are excluded).\n4.  Mechanical Thrombectomy: The patient meets the criteria for mechanical thrombectomy (LVO in anterior circulation, within 6 hours of onset, reasonable pre-stroke function). Current guidelines state that patients eligible for mechanical thrombectomy who have contraindications to IV fibrinolysis (such as an elevated INR) should proceed directly to thrombectomy.\n5.  Reversal Agents:\n    *   Reversing warfarin with PCC to administer alteplase (Option D) is not standard practice for acute ischemic stroke, especially when thrombectomy is immediately available. It introduces delay and potential pro-thrombotic risks.\n    *   Idarucizumab (Option E) is a specific reversal agent for dabigatran, a direct thrombin inhibitor. It is ineffective for reversing warfarin (a vitamin K antagonist).\n\nTherefore, the most appropriate acute intervention is to proceed directly to mechanical thrombectomy without administering intravenous thrombolysis.\n\nThe answer is (B)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123-006", "question": "A 55-year-old man with severe persistent asthma on high-dose inhaled corticosteroids, long-acting beta-agonist, long-acting muscarinic antagonist, and monthly omalizumab presents with continued poor control. Spirometry shows FEV1 45% predicted with 15% bronchodilator response. Laboratory studies reveal blood eosinophils 450 cells/μL, total IgE 850 IU/mL, and FeNO 55 ppb. Sputum analysis shows 8% eosinophils. Despite confirmed adherence and proper inhaler technique, he has had 4 exacerbations requiring systemic corticosteroids in the past year. Which biologic switch would most likely provide additional benefit?", "options": ["Dupilumab targeting IL-4 receptor alpha", "Benralizumab targeting IL-5 receptor alpha", "Mepolizumab targeting IL-5", "Tezepelumab targeting thymic stromal lymphopoietin", "Continue omalizumab with addition of low-dose oral corticosteroids"], "answer": "D", "answer_index": 3, "explanation": "This patient has severe eosinophilic asthma failing omalizumab (anti-IgE) therapy despite elevated biomarkers (eosinophils, FeNO). Tezepelumab targets TSLP, an epithelial cytokine upstream of multiple inflammatory pathways (Th2, ILC2), and has demonstrated efficacy regardless of baseline eosinophil count or IgE levels, including in patients who failed other biologics. While anti-IL-5/IL-5R agents (B, C) and dupilumab (A) target eosinophilic inflammation, tezepelumab's upstream mechanism may provide benefit when anti-IgE therapy has failed despite persistent type 2 inflammation. Adding oral corticosteroids (E) increases adverse effects without addressing the underlying inflammatory pathway.", "generator_model": "claude-opus-4-5-20251101", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "The patient is a 55-year-old man with severe persistent asthma that is uncontrolled despite maximal medical therapy, including high-dose ICS/LABA/LAMA and the biologic omalizumab (anti-IgE). He exhibits a \"Type 2 high\" phenotype characterized by elevated blood eosinophils (450 cells/μL), elevated total IgE (850 IU/mL), elevated FeNO (55 ppb), and sputum eosinophilia.\n\nWhen choosing a switch for a patient failing omalizumab, one must consider the biomarkers present:\n1.  Elevated Blood Eosinophils (450 cells/μL): Predicts response to anti-IL-5 agents (mepolizumab, benralizumab, reslizumab), anti-IL-4/13 agents (dupilumab), and anti-TSLP (tezepelumab).\n2.  Elevated FeNO (55 ppb): FeNO is a biomarker primarily driven by IL-13 activity acting on airway epithelial cells. Anti-IL-5 agents (mepolizumab, benralizumab) typically decrease eosinophils but have minimal effect on FeNO or IL-13-mediated outcomes (such as mucus production and smooth muscle hyperreactivity). In contrast, dupilumab blocks the IL-4 receptor alpha, inhibiting both IL-4 and IL-13 signaling. This mechanism directly suppresses FeNO and addresses the IL-13-driven component of inflammation.\n3.  Low FEV1 (45% predicted): Clinical trials (e.g., LIBERTY ASTHMA QUEST) generally show that dupilumab provides greater improvements in lung function (FEV1) compared to anti-IL-5 agents, particularly in patients with elevated FeNO.\n\nWhile anti-IL-5 agents (Options B and C) would address the eosinophilia, they might not adequately control the IL-13-mediated inflammation evidenced by the high FeNO (55 ppb). Tezepelumab (Option D) is also an effective option that reduces all T2 biomarkers, but dupilumab has strong, specific evidence as the preferred agent when both eosinophils and FeNO are elevated, particularly for maximizing lung function improvement. Option E (OCS) is associated with significant long-term toxicity and should be avoided if a biologic switch is viable.\n\nTherefore, given the combination of high eosinophils and specifically the high FeNO along with the need for lung function improvement, dupilumab is the most mechanistically appropriate choice.\n\nThe answer is (A)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123-007", "question": "A 48-year-old woman is brought to the emergency department after being found unresponsive at home. She has a history of depression. On examination, she is comatose with pinpoint pupils, respiratory rate of 6/min, temperature 35.8°C, and blood pressure 90/60 mmHg. ECG shows QRS duration of 145 ms with a terminal R wave in aVR of 4 mm. After securing the airway and administering naloxone without response, what is the most appropriate next intervention?", "options": ["Intravenous flumazenil 0.2 mg", "Intravenous sodium bicarbonate bolus targeting serum pH 7.50-7.55", "Intravenous lipid emulsion 20% bolus", "Intravenous glucagon 5 mg bolus", "Emergent hemodialysis"], "answer": "B", "answer_index": 1, "explanation": "The clinical presentation (coma, miosis, respiratory depression, hypotension) with ECG findings of QRS widening >100 ms and terminal R wave in aVR >3 mm is classic for tricyclic antidepressant (TCA) toxicity. The sodium channel blockade causing cardiac toxicity is treated with sodium bicarbonate, which increases extracellular sodium (overcoming channel blockade) and alkalinizes serum (increasing protein binding of TCA). Target pH is 7.50-7.55. Flumazenil (A) is contraindicated as it may precipitate seizures in TCA overdose. Lipid emulsion (C) is second-line. Glucagon (D) is for beta-blocker toxicity. Hemodialysis (E) is ineffective for TCAs due to high protein binding and large volume of distribution.", "generator_model": "claude-opus-4-5-20251101", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "B", "model_outputs": "The clinical presentation involves a comatose patient with a history of depression, respiratory depression, hypotension, and specific ECG findings. While the pinpoint pupils and respiratory depression initially suggest opioid toxicity, the administration of naloxone yielded no response.\n\nThe key to this question lies in the ECG findings: a QRS duration of 145 ms (widened) and a prominent terminal R wave in lead aVR (specifically >3 mm). These are hallmark signs of sodium channel blockade, most characteristically associated with Tricyclic Antidepressant (TCA) overdose. While TCAs often cause dilated pupils (due to anticholinergic effects), miosis can occur in severe overdose, co-ingestion (e.g., with opioids or benzodiazepines), or deep coma.\n\nThe management of TCA-induced cardiac toxicity (wide QRS >100 ms, ventricular arrhythmias, or refractory hypotension) is intravenous sodium bicarbonate. This works by increasing serum pH (alkalinization) and increasing extracellular sodium concentration. Alkalinization favors the non-ionized form of the drug, decreasing its binding to sodium channels, while the sodium load directly overcomes the channel blockade. The target serum pH is typically 7.50–7.55.\n\nWhy the other options are incorrect:\n*   A. Intravenous flumazenil: This is a benzodiazepine antagonist. It is contraindicated in mixed overdoses or patients with a wide QRS complex (suspected TCA overdose) because removing the anticonvulsant effect of benzodiazepines can precipitate prolonged, refractory seizures and cardiac instability.\n*   C. Intravenous lipid emulsion: While used as a rescue therapy for severe, refractory toxicity from lipophilic drugs (including TCAs), it is not the first-line intervention. Sodium bicarbonate is the initial standard of care.\n*   D. Intravenous glucagon: This is the antidote for beta-blocker and calcium channel blocker overdoses.\n*   E. Emergent hemodialysis: TCAs are highly protein-bound and have a large volume of distribution, rendering hemodialysis ineffective for removal.\n\nThe answer is (B)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123-008", "question": "A 62-year-old man with longstanding type 2 diabetes presents with a 6-month history of burning pain and numbness in his feet, now extending to mid-calf. Examination reveals absent ankle reflexes, reduced pinprick and vibration sense to the knees bilaterally, and mild weakness of toe extension. Nerve conduction studies show absent sural sensory responses, reduced peroneal motor amplitudes with mildly slowed conduction velocities, and prolonged F-wave latencies. Hemoglobin A1c is 7.2%. He is started on duloxetine with minimal improvement after 8 weeks. Gabapentin is added and titrated to 1800 mg daily with partial response. Which additional intervention has the strongest evidence for further symptomatic improvement?", "options": ["Alpha-lipoic acid 600 mg IV daily for 3 weeks", "Topical capsaicin 8% patch application to affected areas", "Spinal cord stimulation trial", "Transcutaneous electrical nerve stimulation (TENS)", "Acupuncture twice weekly for 12 weeks"], "answer": "C", "answer_index": 2, "explanation": "This patient has painful diabetic peripheral neuropathy refractory to first-line (duloxetine) and second-line (gabapentin) pharmacotherapy. Spinal cord stimulation (SCS) has Level 1 evidence from randomized controlled trials (SENZA-PDN, others) demonstrating significant pain reduction in refractory painful diabetic neuropathy, with FDA approval for this indication. Alpha-lipoic acid (A) has modest evidence primarily from European studies. High-concentration capsaicin (B) provides temporary relief but evidence in diabetic neuropathy is limited. TENS (D) and acupuncture (E) have weaker evidence compared to SCS for refractory cases.", "generator_model": "claude-opus-4-5-20251101", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "C", "model_outputs": "The clinical presentation describes a patient with painful diabetic neuropathy (PDN) who has had an inadequate response to standard first-line and second-line pharmacological treatments (duloxetine and gabapentin). The key to answering this question is identifying the intervention with the strongest evidence for efficacy specifically in patients with PDN who are refractory to medical management.\n\n1.  Medical Management Context: The patient has failed an SNRI (duloxetine) and had only a partial response to a calcium channel alpha-2-delta ligand (gabapentin). Current guidelines (e.g., ADA Standards of Care, expert consensus) suggest that for patients refractory to these medications, further standard oral pharmacotherapy (like adding TCAs or opioids) often has limited additional benefit or higher risk profiles.\n2.  Spinal Cord Stimulation (SCS) (Option C): High-frequency (10-kHz) spinal cord stimulation has recently been evaluated in high-quality randomized controlled trials (such as the SENZA-PDN trial published in *JAMA Neurology*, 2021). This study provided Level I evidence that 10-kHz SCS combined with medical management provides substantial and sustained pain relief in patients with PDN refractory to conventional medical therapy (responder rates ~80% vs 5% in the medical management only group). Based on this strong emerging evidence, the FDA approved this modality for PDN, and updated guidelines (e.g., ADA Standards of Care) recommend considering SCS for refractory cases. A trial of SCS is the standard prerequisite before permanent implantation.\n3.  Alpha-lipoic acid (Option A): While *intravenous* alpha-lipoic acid has shown efficacy in trials (e.g., SYDNEY trial), the requirement for daily IV infusion for 3 weeks makes it impractical for routine chronic management. Oral alpha-lipoic acid has shown mixed or inconclusive results (e.g., NATHAN I trial).\n4.  Capsaicin 8% patch (Option B): The high-concentration capsaicin patch is FDA-approved for PDN and supported by evidence (e.g., STEP study). However, the magnitude of pain relief (effect size) observed in trials is generally modest compared to the robust response rates seen in recent SCS trials for the *refractory* population. It is a valid option, but SCS is currently cited as having particularly strong evidence for \"rescue\" in refractory cases.\n5.  TENS (Option D): Guidelines (e.g., AAN 2011) classify TENS as \"probably effective\" (Level B), but the evidence is generally considered of lower quality and the clinical benefit is often modest and transient compared to SCS.\n6.  Acupuncture (Option E): Evidence is considered weak or inconclusive.\n\nGiven the patient is refractory to standard medical therapy and the question asks for the intervention with the *strongest evidence* for distinct symptomatic improvement in this scenario, the recent high-impact Class I evidence supporting spinal cord stimulation makes it the best answer.\n\nThe answer is (C)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123-009", "question": "A 71-year-old man with COPD GOLD stage III is hospitalized for acute exacerbation. On day 3, despite antibiotics, systemic corticosteroids, and scheduled bronchodilators, he remains dyspneic with respiratory rate 28/min, accessory muscle use, and ABG showing pH 7.31, PaCO2 58 mmHg, PaO2 55 mmHg on 4L nasal cannula. He is alert and cooperative. Bilevel positive airway pressure (BiPAP) is initiated at IPAP 12/EPAP 5 cm H2O. After 2 hours, repeat ABG shows pH 7.29, PaCO2 62 mmHg. He remains tachypneic but is tolerating the mask. What is the most appropriate next step?", "options": ["Increase IPAP to 18 cm H2O and reassess in 1-2 hours", "Proceed with endotracheal intubation and mechanical ventilation", "Add heliox (helium-oxygen mixture) to the BiPAP circuit", "Switch to high-flow nasal cannula at 60 L/min", "Increase EPAP to 10 cm H2O while maintaining IPAP"], "answer": "A", "answer_index": 0, "explanation": "The patient has acute hypercapnic respiratory failure from COPD exacerbation with initial NIV settings that are inadequate (worsening hypercapnia). The driving pressure (IPAP-EPAP = 7 cm H2O) is insufficient for adequate ventilation. Increasing IPAP to 18 cm H2O (driving pressure 13 cm H2O) will augment tidal volume and improve CO2 clearance. Intubation (B) is premature as he is tolerating NIV and is not deteriorating clinically. Heliox (C) reduces airway resistance but doesn't address ventilation. HFNC (D) provides less ventilatory support than BiPAP for hypercapnic failure. Increasing EPAP alone (E) would reduce driving pressure further, worsening ventilation.", "generator_model": "claude-opus-4-5-20251101", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "A", "model_outputs": "This patient with COPD exacerbation and acute hypercapnic respiratory failure is undergoing a trial of non-invasive ventilation (NIV/BiPAP). After 2 hours, he has persistent/worsening respiratory acidosis (pH 7.31 $\\to$ 7.29, PaCO2 58 $\\to$ 62 mmHg). However, he remains alert, cooperative, and is tolerating the interface.\n\nThe initial BiPAP settings were IPAP 12 cm H2O and EPAP 5 cm H2O, resulting in a pressure support (PS) of $12 - 5 = 7$ cm H2O. In patients with COPD exacerbation, the goal of NIV is to unload the respiratory muscles and increase alveolar ventilation to lower PaCO2. A pressure support of 7 cm H2O is often insufficient to achieve these goals in severe exacerbations.\n\nClinical guidelines for NIV in COPD generally recommend starting with IPAP 10-15 cm H2O and titrating up to achieve adequate tidal volume and respiratory rate reduction, often requiring IPAP levels of 15-20 cm H2O or higher (as tolerated). Since the patient is alert and tolerating the mask, the slight worsening in ABG likely reflects inadequate ventilatory support rather than refractory failure of the modality itself. Therefore, the most appropriate step is to optimize the NIV settings by increasing the IPAP to increase the pressure support and minute ventilation.\n\nIncreasing IPAP to 18 cm H2O (Option A) provides a pressure support of 13 cm H2O, which should improve ventilation.\n\nIntubation (Option B) is indicated if the patient becomes obtunded, hemodynamically unstable, unable to protect their airway, or fails to improve despite *optimal* NIV settings. Since the settings have not been optimized, intubation is premature.\n\nSwitching to HFNC (Option D) is generally inferior to NIV for acute hypercapnic respiratory failure with moderate to severe acidosis.\n\nIncreasing EPAP to 10 cm H2O without increasing IPAP (Option E) would decrease the pressure support to 2 cm H2O ($12 - 10$), thereby worsening hypoventilation.\n\nThe answer is (A)"}, {"quiz_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123", "question_id": "20251129T135352000Z_claude-opus-4-5-20251101_seed123-010", "question": "A 38-year-old woman presents with palpitations and near-syncope. ECG shows a regular wide complex tachycardia at 220 bpm with RBBB morphology, northwest axis, and AV dissociation. She is hemodynamically stable with blood pressure 105/70 mmHg. Adenosine 12 mg IV is administered without effect. Procainamide infusion is started, and after 8 minutes (750 mg administered), the rhythm converts to sinus. Post-conversion ECG reveals sinus rhythm with a short PR interval (100 ms), delta waves, and QRS duration of 140 ms with positive delta wave in V1. Which electrophysiologic finding would most strongly support proceeding with catheter ablation rather than medical management?", "options": ["Accessory pathway effective refractory period of 270 ms", "Inducible orthodromic atrioventricular reentrant tachycardia", "Accessory pathway located in the left lateral position", "Shortest pre-excited RR interval during induced atrial fibrillation of 220 ms", "Decremental conduction properties of the accessory pathway"], "answer": "D", "answer_index": 3, "explanation": "This patient has Wolff-Parkinson-White syndrome with documented antidromic AVRT (wide complex tachycardia with AV dissociation, RBBB morphology suggesting left-sided pathway). The most important risk stratification parameter is the shortest pre-excited RR interval (SPERRI) during atrial fibrillation, which reflects the accessory pathway's ability to conduct rapid atrial rates to the ventricle. SPERRI ≤250 ms indicates high-risk pathway capable of conducting AF at rates that could degenerate to ventricular fibrillation, strongly favoring ablation. Accessory pathway ERP (A) is less predictive than SPERRI. Inducible orthodromic AVRT (B) and pathway location (C) don't indicate sudden death risk. Decremental properties (E) actually suggest lower risk.", "generator_model": "claude-opus-4-5-20251101", "seed": 123, "category": "medicine", "difficulty": "very-hard", "not_for_clinical_use": true, "pred": "D", "model_outputs": "This patient presents with a regular wide complex tachycardia with AV dissociation, which is diagnostic of Ventricular Tachycardia (VT). However, the post-conversion ECG clearly demonstrates Wolff-Parkinson-White (WPW) syndrome (short PR, delta wave, wide QRS). The question asks for the finding that most strongly supports catheter ablation acting as the definitive management over medical therapy.\n\nIn patients with WPW syndrome, the primary concern regarding life-threatening risk is the development of atrial fibrillation (AF) with rapid conduction down the accessory pathway, which can degenerate into ventricular fibrillation (VF). Risk stratification is performed to identify patients at high risk for this complication.\n\nThe most validated marker for high risk of sudden cardiac death (SCD) in WPW is a Shortest Pre-Excited RR Interval (SPERRI) during atrial fibrillation of < 250 ms. A SPERRI of 220 ms (Option D) indicates that the accessory pathway is capable of conducting at extremely high rates (approx. 273 bpm), placing the patient at significant risk for VF. This finding constitutes a Class I indication for catheter ablation, rendering medical management alone insufficient and potentially unsafe.\n\nLet's evaluate the other options:\n*   A. Accessory pathway effective refractory period (APERP) of 270 ms: An APERP > 250 ms is generally considered a marker of a lower-risk pathway. This would not strongly argue against medical management compared to a high-risk marker.\n*   B. Inducible orthodromic atrioventricular reentrant tachycardia: This confirms the mechanism of reentrant SVT but does not inherently predict the risk of sudden death. While symptomatic AVRT is an indication for ablation, medical management is a valid alternative for symptom control if the pathway is not high-risk.\n*   C. Accessory pathway located in the left lateral position: While left-sided pathways are common and generally safe to ablate, the location itself does not dictate the necessity of ablation over medical management as strongly as the risk of lethal arrhythmias.\n*   E. Decremental conduction properties: Pathways with decremental conduction (like those seen in PJRT) typically conduct slower appearing as long RP tachycardias and are less likely to conduct rapid AF to the point of VF compared to a pathway with a short, non-decremental refractory period.\n\nDetailed analysis of the clinical scenario: Although the presenting rhythm was VT (indicated by AV dissociation), the discovery of a high-risk accessory pathway (SPERRI 220 ms) in a symptomatic patient mandates ablation of the pathway to prevent sudden death, regardless of the mechanism of the presented stable tachycardia (which may have been a distinct entity or the AV dissociation description distinguishes it from AVRT).\n\nThe answer is (D)"}]